Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

284.70USD
24 Jul 2017
Change (% chg)

$1.78 (+0.63%)
Prev Close
$282.92
Open
$283.00
Day's High
$285.35
Day's Low
$280.01
Volume
1,471,741
Avg. Vol
1,579,752
52-wk High
$333.65
52-wk Low
$244.28

BIIB.O

Chart for BIIB.O

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $60,011.63
Shares Outstanding(Mil.): 212.12
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 17.74 11.79 15.85
EPS (TTM): 15.95 -- --
ROI: 19.24 -10.04 -8.31
ROE: 31.91 -9.89 -7.95

BRIEF-Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders

* Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders

Jul 18 2017

BRIEF-Biogen to present data at Alzheimer's Association International Conference

* Biogen to present data at Alzheimer's Association International Conference 2017 (AAIC) Source text for Eikon: Further company coverage:

Jul 14 2017

BRIEF-Biogen appoints Amy Chevalier Efantis vice president of government affairs

* Biogen appoints Amy Chevalier Efantis vice president of government affairs

Jul 10 2017

Biogen sues to block generic versions of blockbuster MS drug

Biogen Inc on Wednesday sued 13 drugmakers for patent infringement in a bid to block generic versions of its blockbuster multiple sclerosis drug Tecfidera.

Jun 30 2017

BRIEF-Biogen’s Imraldi granted positive opinion by committee for medicinal products for human use

* Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by committee for medicinal products for human use

Jun 23 2017

BRIEF-Biogen appoints Ginger Gregory as chief human resources officer

* Biogen appoints Ginger Gregory executive vice president, chief human resources officer

Jun 20 2017

US STOCKS-Wall St at record highs on technology, health stocks strength

* Fed's Dudley says tight labor market should push inflation up

Jun 19 2017

Alexion taps Biogen veteran Paul Clancy as CFO

Alexion Pharmaceuticals Inc named long-time Biogen Inc Chief Financial Officer Paul Clancy to a similar position, effective July 31, as recently appointed CEO Ludwig Hantson steps up efforts to regain investor confidence.

Jun 13 2017

UPDATE 1-Alexion taps Biogen veteran Paul Clancy as CFO

June 13 Alexion Pharmaceuticals Inc named long-time Biogen Inc Chief Financial Officer Paul Clancy to a similar position, effective July 31, as recently appointed CEO Ludwig Hantson steps up efforts to regain investor confidence.

Jun 13 2017

REFILE-Alexion names Biogen's Paul Clancy as CFO

June 13 Alexion Pharmaceuticals Inc on Tuesday named Biogen Inc's Chief Financial Officer Paul Clancy as its finance head, effective July 31.

Jun 13 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $133.01 -2.30
Pfizer Inc. (PFE.N) $33.32 -0.16
Novartis AG (NOVN.S) CHF79.55 -0.75
Merck & Co., Inc. (MRK.N) $62.57 -0.06
Roche Holding Ltd. (ROG.S) CHF242.60 -1.40
Roche Holding Ltd. (RO.S) CHF243.70 -1.00
Bayer AG (BAYGn.DE) €111.30 +0.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €81.91 +0.39
GlaxoSmithKline plc (GSK.L) 1,595.50 -19.50

Earnings vs. Estimates